Effect of Cornus mas L. fruit extract on lipid accumulation product and cardiovascular indices in patients with non-alcoholic fatty liver disease: A double-blind randomized controlled trial

Sangouni, Abbas Ali; Sangsefidi, Zohreh Sadat; Yarhosseini, Faezeh; Akhondi-Meybodi, Mohsen; Ranjbar, A.M.; Madadizadeh, Farzan

doi:10.1016/j.clnesp.2021.11.023

Cited by 13 publications

(10 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After retrieving the remaining 22 articles, the full texts of each one was carefully reviewed to determine their eligibility. The following four causes led to the exclusion of a 14 further articles: two publications were conference abstracts [ 37 , 38 ]; two of the publications were posters [ 39 , 40 ]; one study involved patients with polycystic ovarian syndrome [ 41 ]; one study enrolled patients under the age of 18 [ 42 ]; one study involved no imagistic or histopathological confirmation of hepatic steatosis [ 43 ]; and seven publications were interventional studies [ 44 , 45 , 46 , 47 , 48 , 49 , 50 ]. Eight publications in total [ 4 , 5 , 51 , 52 , 53 , 54 , 55 , 56 ] were included in the systematic review, and six of these [ 4 , 5 , 51 , 52 , 55 , 56 ] were also included in the meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

(1) Background: Approximately a billion people worldwide are affected by NAFLD, which places a high clinical burden and financial cost on society. Liver biopsy is the gold standard for diagnosing NAFLD, but its invasivity limits the early diagnosis of NAFLD. Hence, it is important to look for alternate techniques in detecting and diagnosing NAFLD. NAFLD is associated with atherosclerosis. The purpose of this study was to assess the effectiveness of the atherogenic index of plasma (AIP) as a non-invasive modality for predicting NAFLD. (2) Methods: A search using electronic databases PubMed, EMBASE, and Scopus was carried out to find observational studies, looking at research that had been published up until the date of 11 May 2022. The included studies’ quality, risk of bias, and internal validity were evaluated using the QUADAS-2 quality assessment tool. The key summary outcomes were the mean difference (MD) and area under the curve (AUC). (3) Results: A total of eight studies (81,178 participants) were included in our review, while 17% of the included participants had NAFLD. A sex distribution of 57.8% men and 42.2% women was observed. The AIP between NAFLD and the controls was not significant (MD 0.212 [95% CI 0.231–0.655]). A significant MD in AIP between the males and females with NAFLD was observed (MD 0.246 [95% CI 0.098–0.395]). The AIP predicted NAFLD with an AUC of 0.764 as well as in males (AUC 0.761) and females (AUC 0.733). (4) Conclusions: There was a substantial MD in the AIP between both sexes, but there was no significant difference in the AIP values between patients with NAFLD and the controls. The AIP is a reliable biomarker for the diagnosis of NAFLD since its ability to predict the development of NAFLD was comparable to that of the other biomarkers.

show abstract

Section: Resultsmentioning

confidence: 99%

Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The LAP index is known as an available and accurate scoring system to estimate cardiometabolic risk and visceral obesity [12][13][14][15]. A RCT evaluated the effect of 12-week L-carnitine supplementation (1000 mg/day) on LAP, and reported that L-carnitine has no effect on LAP among women with PCOS [28].…”

Section: Discussionmentioning

confidence: 99%

“…It has been suggested that atherogenic indices can predict cardiovascular risk better than low density lipoproteincholesterol (LDL-c), triglyceride (TG) or total cholesterol (TC) alone [10,11]. In addition, lipid accumulation product (LAP) as a novel and available index can predict visceral obesity and cardiometabolic risk [12][13][14][15]. The LAP is based on TG and waist circumference (WC) [13].…”

Section: Introductionmentioning

confidence: 99%

Effect of L-carnitine supplementation on lipid accumulation product and cardiovascular indices in women with overweight/obesity who have knee osteoarthritis: a randomized controlled trial

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background Osteoarthritis is associated with obesity, dyslipidemia and cardiovascular diseases. It has been hypothesized that L-carnitine can improve cardiovascular risk factors. We aimed to investigate the effect of L-carnitine supplementation on lipid accumulation product (LAP) and atherogenic indices in women with overweight/obesity who have knee osteoarthritis. Methods In this double-blind randomized controlled trial, seventy-six women with overweight/obesity who had knee osteoarthritis were assigned into the intervention group and control group for 12 weeks. The intervention group received 1000 mg/day L-carnitine as capsule, and the control group received placebo. The primary outcomes were LAP, atherogenic index of plasma (AIP), atherogenic coefficient (AC) and Castelli risk index II (CRI-II). Results We found no significant difference between the groups in baseline values of LAP, AIP, AC and CRI-II. After the intervention, a significant reduction in LAP was observed in intervention group compared to the control group (− 11.05 (− 28.24 to 0.40) vs. − 5.82 (− 24.44 to 2.68); P = 0.03). However, there was no significant difference between two groups in AIP (− 0.05 ± 0.16 vs. − 0.01 ± 0.13; P = 0.19), AC (− 0.40 ± 0.81 vs. − 0.30 ± 0.67; P = 0.67) and CRI-II (− 0.20 ± 0.76 vs. − 0.21 ± 0.47; P = 0.11). Conclusions L-carnitine supplementation for 12 weeks can improve LAP, but it has no effect on cardiovascular outcomes. To reach a definitive conclusion, further clinical trials with larger sample sizes and higher dosages of L-carnitine are needed. Trial registration Registered on 27/4/2017 at Iranian Registry of Clinical Trials IRCT2017011932026N2.

show abstract

“…To date, it has been revealed that FC exhibits anti-inflammation, antivirus, and inhibition of aldose reductase, according to developing attention and studies paid to its biological and pharmaceutical activities [1]. Furthermore, existing studies have indicated that FC could exert certain cardiovascular protection against afflictions like myocardial ischemia, and reperfusion injury and that its efficacy on cardiovascular index improvement needs further research [2,3]. As it has been proven, chemical compounds isolated from FC are recognized as loganin, morroniside, sweroside, and so on, all of which could be majorly categorized into iridoid glycosides, triterpenes, organic acids, tannins as well as other components, respectively.…”

Section: Introductionmentioning

confidence: 99%

Investigate the metabolic profile and potential active compounds of Fructus Corni in the treatment of heart failure by applying ultra‐performance liquid chromatography with quadrupole time‐of‐flight mass spectrometry and network pharmacology

Wang

Chen

et al. 2022

J of Separation Science

View full text Add to dashboard Cite

Fructus Corni has been reported to contain a wide variety of pharmacological effects and previous studies had revealed that Fructus Corni might protect the cardiac indices. However, the all-encompassing metabolic profile of Fructus Corni has not been well illuminated. In this research, high-sensitivity ultra-performance liquid chromatography with quadrupole time-of-flight mass spectrometry method was adopted to identify the metabolic profile after oral administration of Fructus Corni extract, especially the metabolic characterization of serum and heart, for which the targets and signaling pathways about heart failure were hunted through compound-target-disease-pathway intersection network. Ultimately, 37 ingredients were identified in Fructus Corni extract, and 22 prototypes and 134 metabolites that were identified in serum, heart, feces, and urine were tentatively characterized, which contained iridoids, flavonoids, tannins, organic acids, and others. Additionally, 10 putative key compounds including four prototypes and six phase I metabolites were screened by network pharmacology and molecular docking, among which, secoxyloganin (P7), loganin (P14), cornuside III (P17) and cornuside (P20) were the absorbed compounds to represent the potential active ingredients of Fructus Corni engaged in heart failure condition. In general, this method provided the combined strategy to preliminarily settle the complex of Fructus Corni's metabolic profiling and anti-heart failure pharmacologic activities.

show abstract

Effect of Cornus mas L. fruit extract on lipid accumulation product and cardiovascular indices in patients with non-alcoholic fatty liver disease: A double-blind randomized controlled trial

Cited by 13 publications

References 49 publications

Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis

Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis

Effect of L-carnitine supplementation on lipid accumulation product and cardiovascular indices in women with overweight/obesity who have knee osteoarthritis: a randomized controlled trial

Investigate the metabolic profile and potential active compounds of Fructus Corni in the treatment of heart failure by applying ultra‐performance liquid chromatography with quadrupole time‐of‐flight mass spectrometry and network pharmacology

Contact Info

Product

Resources

About